romiplostim (AMG531, Nplate)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

1-7 ug/kg SQ weekly

Adverse effects

Mechanism of action

More general terms

References

  1. Kuter DJ et al, Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008, 371:395 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18242413
  2. Kuter DJ et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010 Nov 11; 363:1889. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21067381
    George JN. Management of immune thrombocytopenia - Something old, something new. N Engl J Med 2010 Nov 11; 363:1959. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21067388
  3. 3.0 3.1 Boggs W Romiplostim Not Tied to Leukemic Progression in Myelodysplastic Syndromes Medscape - Feb 01, 2018 https://www.medscape.com/viewarticle/892138